Why Amneal Is Monday’s Big Biopharma Winner
Amneal Pharma shares hit a post-IPO high in Monday’s session after the company announced a new licensing and supply agreement.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 125
5 Speculative Biotech Analyst Picks With Upside Targets of 100% to 400%
24/7 Wall St. has identified several biotech analyst calls from Wall Street wherein the analysts are projecting upside of 100% to about 400%.
Are Teva and Mylan Entering an EpiPen Price War to Zero?
Mylan has had a stranglehold on the market for EpiPen, but this is all changing after the FDA approved Teva for a generic version of it.
New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug
Teva and Regeneron both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or…
Vertex Wins FDA Approval for Expanded Cystic Fibrosis Treatment
Vertex Pharmaceuticals shares saw a handy gain on Thursday after the FDA gave a nod to Vertex’s cystic fibrosis treatment.
Why Summit Therapeutics Is One of Thursday’s Top Biotechs
Summit Therapeutics shares made a solid gain early on Thursday after the firm announced that it was awarded an additional $12 million under its contract with the Biomedical Advanced Research and Development Authority.
Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive
The latest monthly Merrill Lynch RIC Report is quite favorable on the health care sector as an opportunity for investors. Here we identify some of the top health care picks.
What the FDA Has to Say About Regeneron’s Eylea
Regeneron Pharmaceuticals is facing some difficulty after it received an update from the FDA on Eylea (aflibercept) Injection in patients with wet age-related macular degeneration.
Google Bests Doctors in Eye Disease Treatment
In another sign that artificial intelligence can outthink humans, Google announced it was able to more quickly detect eye disease problems than medical professionals.
Short Sellers Hike Bets in Major Pharma Stocks
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Why Have Short Sellers Backed Off Major Biotechs?
The July 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Why Boston Scientific Could Retest All-Time Highs
Boston Scientific announced early Wednesday morning that it will be in position to submit the final Lotus Edge Premarket Approval next week, with plans to be back in Europe in the first quarter of…
What Analysts Are Saying After Spark Therapeutics Q2 Report
Spark Therapeutics took a massive hit on Tuesday that wiped out about 28% of the share price in the wake of its second-quarter earnings report.
Why Mylan Is Paying the Price for Q2
Mylan reported disappointing quarterly results before the markets opened on Wednesday, and shares retreated afterward.
Ready or Not, Health Care Costs Projected to Rise Another 5% in 2019
Whether you are a consumer or an employer, there is a pretty good chance you would like to have lower costs of health care.